Skip to main content
Psych Regionals Main banner
Back

Optimizing Outcomes for Your Patients with ADHD

Thursday, October 19, 2023
8:00 AM – 9:00 AM USA

    Presenter(s)

  • Greg Mattingly, MD

    Associate Clinical Professor, Washington University in St. Louis; President, Midwest Research Group; Board of Directors, APSARD; Editorial Board, Journal of Attention Disorders
    St.Charles Psychiatric Associates
    Washington University School of Medicine
    St.Charles, Missouri

Disclosure(s):
Greg Mattingly, MD: No relevant disclosure to display
In this session, Dr. Greg Mattingly will examine the developmental nature of ADHD across the lifespan from childhood through adulthood. He will explore the evolving nature of ADHD and impairments encountered as the brain matures throughout childhood, adolescent and adulthood, and he will highlight how ADHD is impacted through concomitant life transitions. In addition, Dr. Mattingly will discuss effective strategies that target changing clinical needs to optimize patient outcomes during these times of developmental transition. Psychopharmacological interventions for children, adolescent and adults with ADHD will be examined through both their mechanisms of action and duration of effects. Throughout the session, particular emphases will be placed upon both the frequent impact of comorbidities on ADHD, as well as effective strategies to overcome treatment gaps for women, young adults, and seniors.

Learning Objectives:

  • Describe how brain maturation impacts the developmental nature of Attention Deficit Hyperactivity Disorder (ADHD) symptomatology and resulting impairments
  • Identify strategies for optimizing care during times of transition and changing clinical needs, in order to improve outcomes and individualize
    care
  • Discuss various pharmacologic interventions that may benefit children, adolescent and adults with ADHD, and how pharmacological needs may change with brain maturation and life transitions
  • Discuss approaches to overcome treatment gaps for women, young adults, seniors and those impacted by comorbidity